Elizabeth Garrett-Mayer to Pancreatic Neoplasms
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Pancreatic Neoplasms.
Connection Strength
0.355
-
Adjuvant radiotherapy and lymph node status for pancreatic cancer: results of a study from the Surveillance, Epidemiology, and End Results (SEER) Registry Data. Am J Clin Oncol. 2014 Apr; 37(2):112-6.
Score: 0.091
-
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):837-44.
Score: 0.090
-
Stromal cell-derived factor 1a mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia. 2012 Aug; 14(8):690-701.
Score: 0.081
-
Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. Mol Cancer Ther. 2007 May; 6(5):1509-16.
Score: 0.056
-
Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001 May; 25(5):579-86.
Score: 0.037